Liposomal formulation of idarubicin
Slifirski, P.; Szelejewski, W.ła.; Grynkiewicz, G.; Gubernator, J.; Kozubek, A.
Acta Poloniae Pharmaceutica 60(2): 138-140
2003
ISSN/ISBN: 0001-6837 PMID: 13678324 Document Number: 555438
Document emailed within 1 workday
Related Documents
Casado, P.; Torreira, C.; Oujo, E.; Esteban, P.; Albo, C.; Diaz, R.; M.A. Andrade 2010: New Liposomal Cytarabine Formulation in CSF Clinical Laboratory 56(1-2): 69-70Stevens, P.J.; Lee, R.J. 2003: Formulation kit for liposomal doxorubicin composed of lyophilized liposomes Anticancer Research 23(1a): 439-442
Boswell, G.W.; Bekersky, I.; Buell, D.; Hiles, R.; Walsh, T.J. 1998: Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats Antimicrobial Agents and ChemoTherapy 42(2): 263-268
Arif, K.; Ejaj, A.; Maroof, A.; Azmat, A.K.; Arun, C.; Fatima, N.; Gatoo, M.A.; Owais, M. 2009: Protective effect of liposomal formulation of tuftsin (a naturally occurring tetrapeptide) against cyclophosphamide-induced genotoxicity and oxidative stress in mice Indian Journal of Biochemistry and Biophysics 46(1): 45-52
Fujita, H.; Ogawa, M.; Masaoka, T.; Yamada, K.; Kimura, K. 1992: A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(6): 791-798
Ogawa, M.; Masaoka, T.; Yamada, K.; Kimura, K. 1993: Early phase Ii study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(7): 897-906
Iwaszkiewicz, K.S.; Hua, S. 2014: Development of an effective topical liposomal formulation for localized analgesia and anti-inflammatory actions in the Complete Freund's Adjuvant rodent model of acute inflammatory pain Pain Physician 17(6): E719-E735
Masaoka, T.; Ogawa, M.; Yamada, K.; Kimura, K.; Ohhashi, Y. 1993: A late phase Ii comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(13): 1995-2005
2002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-178
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
2003: Paracetamol for injection: new formulation. New formulation: why so widely used? Prescrire International 12(67): 178
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Jehl, F.; Klossek, J.M.; Peynegre, R.; Serrano, E.; Castillo, L.; Bobin, S.; Desprez, D.; Renault, C.; Neel, V.; Rouffiac, E.; Borie, C. 2002: Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily Presse Medicale 31(34): 1596-1603
Scheidel, B.; Blume, H.; Walter, K.; von Nieciecki, A.; Babej-Dölle, R.M. 1993: Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation Arzneimittel-Forschung 43(11): 1211-1215
Urabe, A.; Ohno, R.; Kuraishi, Y.; Masaoka, T.; Ohashi, Y.; Ogawa, M. 1999: Clinical effect of idarubicin on malignant lymphoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(9): 1275-1282
Jogi, R.; Garman, M.; Pielop, J.; Orengo, I.; Hsu, S. 2005: Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin Journal of Drugs in Dermatology: Jdd 4(5): 652-656
Hakes, T.B.; Raymond, V. 1987: Phase Ii study of idarubicin in advanced endometrial carcinoma Cancer Treatment Reports 71(5): 535-536
Speth, P.A.; Minderman, H.; Haanen, C. 1989: Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies Seminars in Oncology 16(1 Suppl 2: 2-9